Manufacturers and health systems have shown that vaccines can be quickly and effectively deployed when accompanied by keen political and financial commitments.
BCG remains the only widely available vaccine for TB. Yet the development of a COVID-19 vaccine over the last year shows that there is capacity to rapidly create new vaccines.
Until vaccines that are capable of protecting all populations against TB are developed, treatment is the best option to preventing infection.
Tuberculosis is a global threat and a public health concern on a scale similar to COVID-19.
Vaccines for other diseases are being examined for their protective effects against coronavirus.
Vaccines have ‘non-specific effects’ that have the potential to save millions of lives.